Rosuvastatin, a potent statin for cardiovascular risk reduction, has raised concerns about QTc interval prolongation, a risk factor for torsades de pointes and sudden cardiac death. This study investigates the short-term effect of rosuvastatin on QTc interval compared to atorvastatin in patients with suspected coronary artery disease (CAD).
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality globally, necessitating effective secondary prevention strategies. Clopidogrel and aspirin are widely used antiplatelet therapies, but their comparative efficacy and safety remain debated. This systematic review and individual patient data meta-analysis aimed to compare clopidogrel versus aspirin in preventing recurrent cardiovascular events in patients with established CAD.
Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of kidney failure, necessitating novel therapies to slow disease progression. The Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) trial is a prospective, multi-centre, international, double-blind, randomized, placebo-controlled phase III study evaluating metformin’s efficacy in reducing kidney function decline in ADPKD patients.
Eli Lilly and Company’s Verzenio® (abemaciclib), a CDK4/6 inhibitor, has demonstrated significant improvement in overall survival (OS) in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, high-risk early breast cancer, as reported in the phase 3 monarchE trial. This global, randomized, open-label, multicenter study enrolled 5,637 patients across 600 sites in 38 countries, evaluating two years of Verzenio plus endocrine therapy (ET) against ET alone.
This prospective cohort study investigated the longitudinal impact of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on sarcopenia indicators and biomarkers of neuromuscular junction (NMJ) stability and neuronal health in older men with type 2 diabetes mellitus (T2DM), compared to sitagliptin as a control. Older adults with T2DM are at elevated risk for sarcopenia, characterized by loss of muscle mass, strength, and function, which can exacerbate disability and reduce quality of life.
